
    
      A double-blind, randomized clinical trial of three pharmacological groups in 36 patients with
      a diagnosis of type 2 diabetes mellitus in accordance with the American Diabetes Association
      (ADA) without treatment.

      They will be assigned randomly two groups of 12 patients, each one will receive
      dihydromyricetin 300 mg or metformin 850 mg, two times per day before having break-fast and
      before having dinner during 12 weeks.

      The Area Under the Curve of glucose and insulin will be calculated, total insulin secretion
      (Insulinogenic index), first-phase of insulin secretion (Stumvoll index) and insulin
      sensitivity (Matsuda index).

      This protocol is already approved by the local ethics committee and written informed consent
      it's going to be obtained from all volunteers.

      Statistical analysis will be presented through measures of central tendency and dispersion,
      average and deviation standard for quantitative variables; frequencies and percentages for
      variable qualitative. Qualitative variables will be analyzed by X2, will be used for
      differences inter-group Mann-Whitney U Test and Wilcoxon Test for the within-groups
      differences. It will be considered statistical significance p â‰¤0.05.
    
  